Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise


Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors

See the rest here:
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Related Posts